Production (Stage)
Universal Ibogaine Inc.
IBOGF
$0.018
-$0.0003-1.64%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.48M | 1.38M | 1.55M | 1.72M | 1.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.48M | 1.38M | 1.55M | 1.72M | 1.73M |
| Cost of Revenue | 1.22M | 1.24M | 1.29M | 1.31M | 1.24M |
| Gross Profit | 253.30K | 138.50K | 260.10K | 406.30K | 489.40K |
| SG&A Expenses | 411.70K | 606.40K | 688.90K | 750.50K | 842.80K |
| Depreciation & Amortization | 249.30K | 252.00K | 249.90K | 252.70K | 247.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.99M | 2.19M | 2.32M | 2.38M | 2.33M |
| Operating Income | -508.40K | -808.80K | -767.60K | -663.80K | -600.80K |
| Income Before Tax | -1.07M | -1.66M | -1.61M | -1.51M | -1.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.07 | -1.66 | -1.61 | -1.51 | -1.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.07M | -1.66M | -1.61M | -1.51M | -1.15M |
| EBIT | -508.40K | -808.80K | -767.60K | -663.80K | -600.80K |
| EBITDA | -259.10K | -556.90K | -517.80K | -411.20K | -353.40K |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.19B | 1.17B | 1.05B | 931.36M | 859.89M |
| Average Diluted Shares Outstanding | 1.19B | 1.17B | 1.05B | 931.36M | 859.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |